U.S. markets closed

ProtoKinetix, Incorporated (PKTX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0345+0.0045 (+15.00%)
At close: 02:56PM EDT

ProtoKinetix, Incorporated

412 Mulberry Street
Marietta, OH 45750
United States
740 434 5041

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Clarence Edward SmithChairman, CEO & PresN/AN/A1964
Mr. Michael Richard Guzzetta CPAChief Financial Officer60kN/A1958
Dr. Jean-Charles Quirion Ph.D.Head of Researchers for RouenN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry-eye diseases. It has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Marietta, Ohio.

Corporate Governance

ProtoKinetix, Incorporated’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.